Gallagher Kathleen P.

Gallagher Kathleen P., Chief Program Officer at an undisclosed company, has demonstrated a clear selling bias in her recent insider transactions, primarily involving shares of RNA (Avidity Biosciences). Over 24 reported trades, her total sell activity amounts to $3.62 million, dwarfing her $184,181 in total buys. The most significant dispositions occurred on December 17, 2025, when she sold RNA shares worth $577,116 and $2.40 million in separate transactions. Earlier that year, she executed multiple sales, including a $172,807 transaction on March 3, 2025, and a $188,918 sale on February 3, 2025, with smaller dispositions clustered in January 2025. Her only recent acquisitions were modest purchases linked to equity awards—$86,362 and $97,818 in March and February 2025, respectively—likely tied to vested awards rather than open-market buys. Notably, Gallagher’s activity in RNAM (unidentified ticker) shows a series of transactions on February 27, 2026, all reported with $0 value, suggesting derivative adjustments or non-monetary transfers. The absence of recent buys and the concentration of high-value sales in RNA indicate a sustained reduction in her equity position. While her December 2025 dispositions represent the peak in dollar terms, the pattern of smaller, earlier sales suggests a gradual unwinding rather than a single strategic exit. The data reflects a consistent trend of monetizing holdings rather than accumulating shares in the disclosed companies.